
    
      This is a Phase II, open label study to assess the efficacy, safety and tolerability of
      VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung
      adenocarcinoma after failure of at least one prior chemotherapeutic regimen. Eligible
      patients will be enrolled as a single cohort and treated with VAL401, given as oral capsules.
      VAL401 is a formulation of Risperidone (active pharmaceutical ingredient) in a liquid lipid
      filled capsule.
    
  